Red Light Holland and ASX-listed Creso Pharma are merging to form HighBrid Lab. TRIP CEO Todd Shapiro to lead the combined entity.
Red Light Holland and ASX-listed Creso Pharma are merging to form HighBrid Lab. TRIP CEO Todd Shapiro to lead the combined entity.
A bill to decriminalize drug possession has been introduced into Congress. If passed, jurisdiction for drug classifying would move from the Justice Department to the Department of Health and Human Services.
Field Trip completes another preliminary step toward its Phase I clinical trial of FT-104.
Atai Life Sciences has re-filed with the SEC to increase its IPO financing from $100 to $246 million. It's a big deal.
HaluGen Life Sciences' test evaluates an individual's overall sensitivity and risk profile associated with psychedelic-assisted therapy
Co-Founder JR Rahn has stepped down as CEO of MindMed. His replacement, Robert Barrow, brings a wealth of clinical trials experience.
JR Rahn is stepping down as MindMed's CEO, to be replaced by Chief Development Officer, Robert Barrow.
Mydecine announces identifying 40 previously unknown "novel compounds" among dozens of mushroom species it has screened.
Cybin is launching a new clinical trial to address "COVID-related burnout and distress", supported by its new EMBARK psychotherapy model.
Red Light Holland's new tech acquisition is intended to help optimize psychedelics dosing.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now